|
Baseline clinical characteristics (N = 38)
|
|
Clinical characteristics
|
|
Men/women, N/N (%/%)
|
13/6 (68/32)
|
12/7 (63/37)
|
1.00
|
|
Age (y), median (IQR)
|
44 (31–54)
|
47 (37–53)
|
0.863
|
|
Comorbidity
|
|
Allergic sensitizaion, N (%)
|
10 (53)
|
10 (53)
|
1.00
|
|
Asthma, N (%)
|
5 (26)
|
10 (53)
|
0.184
|
|
AERD, N (%)
|
3 (16)
|
7 (37)
|
0.269
|
|
Total NP score, median (IQR)
|
4 (3–5)
|
4 (4–6)
|
0.644
|
|
Total symptom score, median (IQR)
|
8 (7–12)
|
9 (8–12)
|
0.443
|
|
Tissue biomarkers, median (IQR)
|
|
IL-5 (pg/ml)
|
86.02 (43.00–237.87)
|
228.14 (133.24–484.44)
|
< 0.05
|
|
Detectable IL-5, N (%)
|
10 (53)
|
16 (84)
|
0.079
|
|
IL-5Rα (pg/ml)
|
2704.74 (1116.04–13,162.88)
|
15,383.50 (4036.26–28,350.59)
|
< 0.05
|
|
TGF-β1 (pg/ml)
|
8934.18 (7356.03–15,825.42)
|
12,769.26 (7562.52–27,256.90)
|
0.477
|
|
MPO (ng/ml)
|
5251.91 (2634.00–11,020.06)
|
9255.17 (4602.93–19,868.30)
|
0.061
|
|
IL-18 (pg/ml)
|
14,982.30 (7761.63–25,611.80)
|
15,051.30 (4698.93–19,633.68)
|
0.354
|
|
ECP (mg/l)
|
5.71 (0.86–12.93)
|
13.48 (4.75–28.46)
|
< 0.05
|
|
Total IgE (kU/l)
|
322.95 (146.30–1348.16)
|
432.30 (251.83–1156.39)
|
0.639
|
|
Detectable IgE to SAE, N (%)
|
8 (42)
|
8 (42)
|
1.00
|
|
Nasal secretion biomarkers, median (IQR)
|
|
IL-5 (pg/ml)
|
30.00 (30.00–109.22)
|
94.81 (30.00–169.86)
|
0.285
|
|
IL-5Rα (pg/ml)
|
667.55 (439.40–791.74)
|
2897.67 (562.93–10,030.07)
|
0.076
|
|
ECP (mg/l)
|
0.36 (0.12–0.79)
|
0.54 (0.32–3.57)
|
0.100
|
|
IgE (kU/l)
|
174.15 (40.49–312.94)
|
324.35 (100.14–662.78)
|
0.394
|
|
Serum biomarkers, median (IQR)
|
|
IL-5 (pg/ml)
|
BDL
|
BDL
|
ND
|
|
IL-5Ra (pg/ml)
|
334.60 (235.60–710.05)
|
414.90 (364.30–866.60)
|
0.471
|
|
ECP (µg/l)
|
26.10 (21.60–45.15)
|
23.90 (19.75–189.50)
|
0.601
|
|
IgE (kU/l)
|
217.00 (51.15–715.00)
|
50.20 (29.35–189.50)
|
0.110
|
